Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Some diabetes meds might lower risk of dementia, Parkinson's
A specific class of diabetes drug appears to lower people's risk for dementia and Parkinson's disease, a new study shows. Sodium-glucose cotransporter-2 (SGLT2) inhibitors, also known as gliflozins, lower blood sugar by prompting the kidneys to filter sugar out of the bloodstream and excrete it in urine,
Some diabetes drugs tied to lower risk of dementia, Parkinson's disease
A class of drugs for diabetes may be associated with a lower risk of dementia and Parkinson's disease, according to a study published in the September 18, 2024, online issue of Neurology.
Some diabetes medications linked to lower dementia, Parkinson's disease risk
For Alzheimer's disease, the incidence rate for people taking SGLT2 inhibitors was 39.7 cases per 10,000 person-years, compared to 63.7 cases for those taking other diabetes drugs. Person-years represent both the number of people in the study and the amount of time each person spends in the study.
Type 2 drugs could lower dementia, Parkinson's disease risk
Researchers have found that people who take a type of type 2 diabetes drugs SGLT2 inhibitors have a significantly lower risk of dementia, overall, and of Alzheimer's disease and Parkinson's, in particular.
Some Diabetes Meds Could Lower Odds for Dementia, Parkinson's
A specific class of diabetes drug appears to lower people’s risk for dementia and Parkinson’s disease, a new study
SGLT2 inhibitors reduce dementia, Parkinson’s disease risk: study
Sodium-glucose cotransporter-2 (SGLT2) inhibitors, a class of diabetes drugs also known as gliflozins, could lower the risk for dementia and Parkinson’s disease, a new study finds.
These Diabetes Drugs Could Help Lower Your Risk of Dementia, Parkinson’s
According to a new study, certain diabetes medications may significantly reduce this risk. These drugs, called gliflozins or SGLT2 inhibitors, stop the kidneys from reabsorbing too much blood glucose to improve blood sugar levels.
Some Diabetes Drugs May Protect Against Dementia and Parkinson's
Scientists found a 22 percent lower risk of any dementia and Parkinson's among a group taking SGLT2 inhibitors for type 2 diabetes.
Daily
8d
Study Reveals Significant Care Gap in SGLT2 Inhibitor Use for Diabetes and HF, Despite Real-World Benefits
Recent study highlights a significant care gap due to the underuse of SGLT2 inhibitors, despite their benefits. Canada: A ...
Medscape
9d
Do SGLT2 Inhibitors Benefit Everyone With T2D and CKD?
New data suggest that current recommendations overstate the proportion of patients who would receive significant kidney ...
Endocrinology Advisor
1d
SGLT2 Inhibitors Cut Kidney Risks Across CKD, Heart Failure, Diabetes Spectrum
The kidney health benefits of SGLT2 inhibitors extend to patient subgroups with chronic kidney disease (CKD) in combo with other conditions.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
New SEC stock pricing rule
30 yrs in prison for assault
AC mayor, wife indicted
US healthcare system falls
Statue damaged by vandal
UN backs Palestine
Existing home sales drop
California deepfake ban
House rejects funding bill
FBI disrupts hacker group
Deal to build new arena
US jobless claims fall
Retaliated against scientists
'Hidden Figures' honored
Trump's New York rally
KY conversion therapy ban
X back for some in Brazil
US launches online renewals
Cancer deaths decline
Port workers to strike?
Opposes Israel arms sales
Super harvest moon eclipse
Shared hacked Trump info
Denied bail again
Portland gets WNBA team
Union opts to not endorse
Los Angeles dengue cases
Fed cuts interest rate
Top Texas officials sued
Sets new WNBA record
Toy Hall of Fame finalists
Pleads not guilty
FL Python Challenge winner
Completes acquisition
Related topics
Parkinson's disease
diabetes
Feedback